The mouse vaccinated assay investigating the immunogenicity of the lipo-gp350D123 nanoparticle vaccine showed that the vaccine could effectively activate the B-cell immune response with a high titer of gp350D123 protein-specific antibody and neutralizing antibody to block EBV-GFP infection in an in vitro cell model, and also activate the CD8+ IFN-γ+ based T-cell immune response. The gene discussed is CD8A; the disease is infection.